|
CN112261948A
|
|
Use of recombinant alkaline phosphatase for the treatment of sepsis-related acute kidney injury
|
|
CN112029753A
|
|
Downstream treatment of alkaline phosphatase
|
|
AU2015209783A1
|
|
Chimeric alkaline phosphatase-like proteins
|
|
AU2013203284A1
|
|
Modified phosphatases
|
|
EP3222286A1
|
|
The use of alkaline phosphatase for preserving renal function
|
|
EP2030980A1
|
|
Mutants of lactoferrin
|
|
EP1985697A1
|
|
Modified phosphatases
|
|
EP1952823A1
|
|
The use of alkaline phosphatase in the treatment of reduced renal function
|
|
AU2005210581A1
|
|
Use of alkaline phosphatase for the detoxification of LPS present at mucosal barriers
|
|
EP1360961A1
|
|
Use of antimicrobial peptides for potentiating the activity of antimicrobial agents
|
|
EP1228772A1
|
|
Novel bone cement containing bioactive agents
|
|
WO0156627A1
|
|
Medical device coated with antimicrobial peptides
|
|
AU3248401A
|
|
Medical device coated with antimicrobial peptides
|
|
US7060677B1
|
|
Antimicrobial activity of the first cationic cluster of human lactoferrin
|
|
WO0134641A2
|
|
Antimicrobial activity of the first cationic cluster of human lactoferrin
|
